Dec 5 (Reuters) - OS Therapies Inc OSTX.A:
OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2
OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2
OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2
Source text: [ID:]
Further company coverage: OSTX.A
((Reuters.Briefs@thomsonreuters.com;))